Unexplained Hypoglycaemia and Large Glycaemic Variability: Skin Lipohypertrophy as a Predictive Sign

Authors

  • Felice Strollo
  • Giuseppina Guarino
  • Vincenzo Armentano
  • Gennaro Clemente
  • Emilia Martedì
  • Stefano de Riu

DOI:

https://doi.org/10.17140/DROJ-2-126

Abstract

Rationale and Aims of the Study: Strong efforts to keep DM under control cause frequent hypoglycaemic events (Hypos) with relevant clinical, social and economic consequences. Moreover, long-lasting rebound hyperglycaemia and patients’ poor compliance or exaggerated corrective behaviors cause high glucose variability (GV). Several Hypos are unexplained and might be due to inappropriate insulin administration. In fact, the reported association between lipohypertrophy (LH) and Hypos might depend on poor education. The purpose of this study was to assess whether LH rate might predict Hypos and GV in insulin treated patients. Methods: This was an observational, retrospective, multicentre study involving 387 DM patients referred to specialized settings for Hypos and/or GV carefully performing self monitoring blood glucose (SMBG) and filling in a structured Hypo questionnaire. Results: Twenty-eight percentages had at least one severe and 72% one non-severe episode (average: 3.3 Hypos/week). T1DM, long standing disease and high insulin doses were significantly associated with LH and impressive odds ratio (ORs) were reached by unexplained Hypos/GV (UHGV; p<0.001). The presence of LH predicted about 77.1% of UHGV, which displayed a 4.38 times higher risk when LH was combined with low socio-economic level, loneliness, poor metabolic control, disease complications and inappropriate injection technique (longer/larger and/or reused needles, missed injection site rotation). In multivariate analysis, the latter was still strongly associated with UHGV. Conclusions: In the presence of UHGV, injection sites should be systematically explored in search of LH areas. Furthermore, appropriate educational activities should be implemented to improve patients’ behavior, including periodical verification of their injection habits.

References

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabe-tes. N Engl J Med. 2008; 359: 1577-1589. doi: 10.1056/NEJ-Moa0806470

Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabe-tes. N Engl J Med. 2008; 358: 2545-2559. doi: 10.1056/NEJ-Moa0802743

Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes. 2008; 57: 3169-3176. doi: 10.2337/db08-1084

Goto A, Arah OA, Goto M, Ierauchi Y, Noda M. Severe hy-poglycemia and cardiovascular disease: Systematic review and meta-analysis with bias analysis. BMJ. 2013; 347: f4533. doi: 10.1136/bmj.f4533

Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older pa-tients with type 2 diabetes mellitus. JAMA. 2009; 301: 1565- 1572. doi: 10.1001/jama.2009.460

Yaffe K, Falvey CM, Hamilton N, et al. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med. 2013; 173: 1300- 1306. doi: 10.1001/jamainternmed.2013.6176

Hsu PF, Sung SH, Cheng HM, et al. Association of clinical symptomatic hypoglycemia with cardiovascular events and to-tal mortality in type 2 diabetes: A nationwide population-based study. Diabetes Care. 2013; 36: 894-900. doi: 10.2337/dc12- 0916

Leiter LA, Yale J-F, Chiasson J-L, et al. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hy-poglycemia management. Can J Diabetes. 2005; 29: 186-192.

Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycae-mia in type 2 diabetes. Diabet Med. 2008; 25: 245-254. doi:

1111/j.1464-5491.2007.02341.x 10. Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: A population-based study of health service resource use. Diabetes Care. 2003; 26: 1176-1180. doi: 10.2337/dia-care.26.4.1176

Willis WD, Diago-Cabezudo JI, Madec-Hily A, Aslam A. Medical resource use, disturbance of daily life and burden of hypoglycemia in insulin-treated patients with diabetes: Results from a European online survey. Expert Rev Pharmacoecon Out-comes Res. 2013; 13: 123-130. doi: 10.1586/erp.12.80

Graveling AJ, Frier BM. Hypoglycaemia: An over-view. Prim Care Diabetes. 2009; 3: 131-139. doi: 10.1016/j. pcd.2009.08.007

Barendse S, Singh H, Frier BM, Speight J. The impact of hy-poglycaemia on quality of life and related patient-reported out-comes in type 2 diabetes: A narrative review. Diabet Med. 2012; 29: 293-302. doi: 10.1111/j.1464-5491.2011.03416.x

Nicolucci A, Cucinotta D, Squatrito S, et al. Clinical and socio-economic correlates of quality of life and treatment satis-faction in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2009; 19(1): 45-53. doi: 10.1016/j.numecd.2007.12.005

Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes. 2008; 57: 3169-3176.

Briscoe VJ, Davis SN. Hypoglycemia in type 1 and type 2 diabetes: Physiology, pathophysiology, and management. Clin Diabetes. 2006; 24: 115-121. doi: 10.2337/diaclin.24.3.115

Workgroup on Hypoglycemia, American Diabetes Associa-tion. Defining and reporting hypoglycemia in diabetes: A report from the American Diabetes Association Workgroup on Hypo-glycemia. Diabetes Care. 2005; 28: 1245-1249. doi: 10.2337/ diacare.28.5.1245

Barnett AH, Cradock S, Fisher M, Hall G, Hughes E, Middle-ton A. Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. Int J Clin Pract. 2010; 64: 1121-1129. doi: 10.1111/j.1742-1241.2009.02332.x

The DCCT Research Group. Epidemiology of severe hypo-glycemia in the diabetes control and complications trial. Am J Med. 1991; 90: 450-459. doi: 10.1016/0002-9343(91)80085-Z

The DCCT Research Group. Hypoglycemia in the diabetes control and complications trial. Diabetes. 1997; 46: 271-286. doi: 10.2337/diab.46.2.271

Donnelly LA, Morris AD, Frier BM, et al. Frequency and predictors of hypoglycemia in type 1 and insulin-treated type 2 diabetes: A population based study. Diabet Med. 2005; 22: 749- 755. doi: 10.1111/j.1464-5491.2005.01501.x

Heller SR, Choudhary P, Davies C, et al. Risk of hypogly-caemia in types 1 and 2 diabetes: Effects of treatment modali-ties and their duration. Diabetologia. 2007; 50: 1140-1147. doi: 10.1007/s00125-007-0599-y

Pedersen-Bjergaard U, Pramming S, Thorsteinsson B. Recall of severe hypoglycaemia and self-estimated state of awareness in type 1 diabetes. Diabetes Metab Res Rev. 2003; 19: 232-240. doi: 10.1002/dmrr.377

International Diabetes Federation. Clinical guidelines task force. Global guideline for type 2 diabetes. 2012. Web site. http://www.idf.org/guideline-type-2-diabetes. Accessed July 26, 2016

Gentile S, Agrusta M, Guarino G, et al. Metabolic conse-quence of incorrect insulin administration techniques in aging subjects with diabetes. Acta Diabetol. 2011; 48: 121-125. doi: 10.1007/s00592-009-0172-x

Young RJ, Hannan WJ, Frier BM, Steel JM, Duncan JPL. Diabetic lipohypertrophy delays insulin absorption. Diabetes Care. 1984; 7: 479-480. doi: 10.2337/diacare.7.5.479

Vardar B, Kizilci S. Incidence of lipohypertrophy in diabetic patients and a study of influencing factors. Diabetes Res Clin Pract. 2007; 77: 231-236. doi: 10.1016/j.diabres.2006.12.023

Blanco M, Hernández MT, Strauss KW, Amaya M. Preva-lence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013; 39: 445-453. doi: 10.1016/j.diabet.2013.05.006

Rosak C, Burkard G, Hoffmann JA, Humburg E, Look D, Landgraf R. Metabolic effect and acceptance of an insulin pen treatment in 20,262 diabetic patients. Diab Nutr Metab. 1993; 6: 139-145. Web site. http://cat.inist.fr/?aModele=afficheN&cp sidt=4911401. Accessed 2016

Chowdhury TA, Escudier V. Poor glycaemic control caused by insulin induced lipohypertrophy. Br Med J. 2003; 327: 383- 384. doi: 10.1136/bmj.327.7411.383

Strauss K, De Gols, Hannet I, Partanen T-M, Frid A. A pan-europen epidemiologic study of insulin injection technique in patients with diabetes. Pract Diab Int. 2002; 19: 71-76. doi: 10.1002/pdi.314

Giorda CB, Ozzello A, Gentile S, et al. HYPOS-1 Study Group of AMD. Incidence and risk factors for severe and symp-tomatic hypoglycemia in type 1 diabetes. Results of the HY-POS-1 study. Acta Diabetol. 2015; 52: 845-853. doi: 10.1007/ s00592-015-0713-4

Giorda CB, Ozzello A, Gentile S, et al. Incidence and cor-relates of hypoglycemia in type 2 diabetes. The Hypos-1 study. J Diabetes Metab. 2014; 5: 3.

American Diabetes Association. Clinical practice recom-mendations 2008. Hypoglycaemia and employment/licensure. Diabetes Care. 2008; 31(Suppl 1): S94.

American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care. 2012; 35(Supp 1): S11-S63. doi: 10.2337/dc12-s011

de Coninck C, Frid A, Gaspar R, et al. Results and analy-sis of the 2008-2009 insulin injection technique questionnaire survey. J Diabetes. 2010; 2: 168-179. doi: 10.1111/j.1753- 0407.2010.00077.x

Gentile S, Guarino G, Giancaterini A, Guida P, Strollo F, AMD-OSDI Italian Injection Technique Study Group. A suitable palpation technique to identify skin lipohypertrophic lesions in insulin-treated people with diabetes. Springe Plus. 2016; 5: 563. doi: 10.1186/s40064-016-1978-y

Gentile S, Strollo F, Guarino G, et al on behalf of the AMD-OSDI* Italian Study Group. Factors hindering correct identifi-cation of unapparent lipohypertrophy. J Diabetes Metab Disord Control. 2016; 3(2): 00065. Web site. http://medcraveonline. com/JDMDC/JDMDC-03-00065.pdf. Accessed July 26, 2016

Pedersen-Bjergaard U, Agerholm-Larsen B, Pramming S, Hougaard P, Thorsteinsson B. Activity of angiotensin-convert-ing enzyme and risk of severe hypoglycaemia in type 1 diabetes mellitus. Lancet. 2001; 357: 1248-1253. doi: 10.1016/S0140- 6736(00)04405-6

Mills GA, Horn JR. Beta-blockers and glucose control. Drug Intell Clin Pharm. 1985; 19: 246-251. Web site. http://euro-pepmc.org/abstract/med/2861072. Accessed July 26, 2016

Connelly KA, Yan AT, Leiter LA, Bhatt DL, Verma S. Car-diovascular implications of hypoglycemia in diabetes mellitus. Circulation. 2015; 132(24): 2345-2350. doi: 10.1161/CIRCU-LATIONAHA.115.015946

Edridge CL, Dunkley AJ, Bodicoat DH, et al. Prevalence and incidence of hypoglycaemia in 532,542 people with type 2 diabetes on oral therapies and insulin: A systematic review and meta-analysis of population based studies. PLoS One. 2015; 10(6): e0126427. doi: 10.1371/journal.pone.0126427

Downloads

Published

2016-08-10

How to Cite

Felice Strollo, Giuseppina Guarino, Vincenzo Armentano, Gennaro Clemente, Emilia Martedì, & Stefano de Riu. (2016). Unexplained Hypoglycaemia and Large Glycaemic Variability: Skin Lipohypertrophy as a Predictive Sign. Diabetes Research, 2(1), 24–32. https://doi.org/10.17140/DROJ-2-126